Tidal Investments’s NewAmsterdam Pharma NAMS Stock Holding History

Tidal Investments’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$717K	Buy	22,400 +20,000	+833%	+$651K	﹤0.01%	1667
2025 Q4	$84.2K	Buy	+2,400	New	+$87.3K	﹤0.01%	2080

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Tidal Investments's NAMS Position: Q1 2026 in Review

Tidal Investments opened a new position in NewAmsterdam Pharma (NAMS) in Q1 2026: 22,458 shares worth $719K. The stake represents ﹤0.01% of the portfolio and ranks #1665 among its holdings.

170 funds tracked by Wall St. Rank hold NAMS as of Q1 2026.

Tidal Investments held 22,458 shares of NewAmsterdam Pharma worth $719K as of Q1 2026.
NewAmsterdam Pharma was a new Tidal Investments position in Q1 2026.
NewAmsterdam Pharma made up ﹤0.01% of Tidal Investments's portfolio in Q1 2026, its #1665 holding.
170 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q1 2026.

Based on Tidal Investments's 13F filing for Q1 2026, filed 15 May 2026.